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SCIENTIFIC LETTER
Clopidogrel reduces platelet–leucocyte aggregation,
monocyte activation and RANTES secretion in type 2
diabetes mellitus
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P
atients with diabetes mellitus have an increased risk of
developing atherosclerosis and its sequelae.
Atherosclerosis is an inflammatory disease involving
multiple interactions between platelets, leucocytes and
endothelial cells.1 Clopidogrel, a specific antagonist of the
ADP P2Y12 receptor, inhibits both platelet activation and
aggregation induced by ADP.2 Although clopidogrel has well-
documented antithrombotic actions, its potential anti-
inflammatory effects have been little investigated. We
examined whether specific platelet inhibition with clopido-
grel would reduce systemic inflammatory markers and
specifically platelet, monocyte and endothelial activation in
patients with type 2 diabetes mellitus.
METHODS
We enrolled 20 patients with type 2 diabetes mellitus without
clinical evidence of cardiovascular disease, malignancy,
chronic inflammatory disorders, intercurrent illness, renal
or hepatic insufficiency or contraindications to clopidogrel
who had not taken antiplatelet agents within the preceding
two weeks. Ethical approval was obtained from the local
ethics committee and all participants provided written
informed consent. They were treated with clopidogrel
75 mg daily for 28 days. Fasting peripheral venous blood
samples were obtained at baseline and at 28 days.
Plasma concentrations of soluble CD40 ligand (sCD40L)
(Bender MedSystems) and sE-selectin (R&D Systems) were
determined by enzyme-linked immunosorbent assays.
Plasma concentrations of the chemokine regulated on
activation normal T cell expressed presumed secreted
(RANTES, CCL5) were assessed with the human chemokine
flow cytometric bead array (BD Biosciences).
To evaluate CD40L and P-selectin on platelets, whole blood
was diluted 1:10 with phosphate-buffered saline (PBS) and
incubated with anti-CD42a:fluorescein isothiocyanate (FITC)
(Serotec),anti-P-selectin:phycoerythrin(PE)(DakoCytomation),
anti-CD40L:PE (DakoCytomation) and appropriate isotype
controls for 20 min before the cells were fixed with 1%
paraformaldehyde. To evaluate CD40 and CD11b on
monocytes, blood was diluted 1:2 with PBS and incubated
with the following monoclonal antibodies: anti-CD14:FITC
(Serotec), anti-CD40:PE (Serotec), anti-CD11b:PE (Serotec)
and appropriate isotype-matched controls for 20 min.
Thereafter, samples were fixed and the red cells lysed by
the addition of FACS-Lyse (Becton Dickinson). To deter-
mine platelet–monocyte and platelet–neutrophil binding,
whole blood was diluted 1:2 with PBS and incubated with
anti-CD14:PE (DakoCytomation) and anti-CD42a:FITC or
isotype-matched controls for 20 min at room temperature,
before FACS-Lyse was added. Platelet–monocyte and
platelet–neutrophil aggregates were defined as monocytes
or neutrophils positive for CD42a. At least 2500 cells were
measured by flow cytometry (EPICS XL2; Beckman-Coulter).
Samples were analysed with EXPO 32 software (Cytometry
Systems).
Continuous variables are reported as mean (SD). Data were
statistically analysed with a paired t test for normally
distributed variables or the Wilcoxon matched pairs test for
non-parametric variables. GraphPad Prism (GraphPad
Software, San Diego, California, USA) was used for all
statistical analyses. Significance was taken at p , 0.05.
RESULTS
Participants (51 (7) years) had a diagnosis of diabetes for 6
(4) years with mean haemoglobin A1c of 7.9 (1.4)%
indicating moderate glycaemic control. Baseline and four-
week fasting plasma glucose concentrations, haemoglobin
A1c and fasting lipid profiles were similar (data not shown,
NS).
Clopidogrel treatment reduced platelet surface P-selectin
(5.6 (2.8)% v 3.7 (1.8)%, p = 0.002) but not CD40L
expression (3.3 (0.7)% v 3.4 (1.0)%, p = 0.7). Monocyte
surface expression of CD40 (40.7 (5.9)% v 35.0 (6.5)%,
p = 0.007) and CD11b (74.8 (7.5) v 60.0 (5.9) mean
fluorescence intensity, p = 0.02) were reduced after clopi-
dogrel treatment. Clopidogrel treatment reduced both plate-
let–monocyte (23.2 (7.6)% v 17.8 (7.4)%, p = 0.01) and
platelet–neutrophil (7.7 (2.9)% v 6.0 (2.3)%, p = 0.04)
binding (fig 1).
Plasma concentrations of the platelet-derived chemokine
RANTES (3722 (1123.0) pg/ml v 1476 (1229) pg/ml,
p , 0.0001) were greatly reduced. However, concentrations
of sCD40L (0.24 (0.42) ng/l v 0.23 (0.32) ng/l, p = 0.24) and
sE-selectin (67.8 940.3) ng/ml v 70.0 (40.5) ng/ml, p = 0.44)
were unchanged after clopidogrel treatment.
DISCUSSION
Over the past decade it has become apparent that complex
signalling occurs between platelets, leucocytes and endothe-
lial cells, and that these interactions have proinflammatory
and proatherosclerotic consequences.1 3 Xiao and The´roux4
have previously reported that clopidogrel attenuated the
excess platelet–monocyte and platelet–neutrophil conjugates
in patients with acute coronary syndromes. Consistent with
these findings, our results show that clopidogrel treatment in
patients with diabetes mellitus also reduces platelet–leuco-
cyte conjugates despite considerably lower levels of platelet
activation. In addition, we have shown that clopidogrel was
associated with less monocyte surface expression of CD40
and CD11b indicating reduced monocyte activation.
Reduction of platelet–leucocyte interactions and monocyte
Abbreviations: FITC, fluorescein isothiocyanate; PBS, phosphate-
buffered saline; PE, phycoerythrin; RANTES, regulated on activation
normal T cell expressed presumed secreted; sCD40L, soluble CD40
ligand
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activation may well contribute to the clinical benefits of
clopidogrel.
RANTES mediates monocyte and lymphocyte recruitment
to sites of vascular injury and has a key role in the
progression of atherosclerosis. RANTES may be secreted by
several cell types including activated platelets and leuco-
cytes.3 In our study clopidogrel reduced both platelet and
monocyte activation and it is therefore not surprising that
clopidogrel also greatly reduced plasma RANTES concentra-
tions. This reduced RANTES secretion provides another
potential anti-inflammatory mechanism that may contribute
to the clinical benefits of clopidogrel.
CD40L has been shown to mediate a broad range of
proinflammatory and prothrombotic responses. In contrast to
P-selectin and RANTES, neither platelet surface expression of
CD40L nor sCD40L was reduced by clopidogrel. Variable
effects of clopidogrel on sCD40L have previously been
reported. Xiao and The´roux4 reported a 27% reduction in
plasma concentrations of sCD40L in patients with acute
coronary syndromes, whereas Quinn et al5 found that
clopidogrel did not affect pre- or post-procedure sCD40L
concentrations in patients undergoing percutaneous coronary
intervention. In the present study, baseline platelet activation
and sCD40L levels were substantially lower than in the acute
coronary syndrome population studied by Xiao and The´roux,4
in which the sCD40L reductions were greatest with baseline
concentrations . 0.5 ng/ml. In our study only one partici-
pant had an sCD40L concentration . 0.5 ng/ml and in this
patient clopidogrel caused a 23% reduction. These findings
suggest that clopidogrel may not have the same effect on
CD40L in patients with lower baseline levels of platelet
activation and sCD40L.
In conclusion, clopidogrel treatment in patients with type 2
diabetes mellitus not only reduces platelet activation but also
reduces platelet–leucocyte interactions, monocyte activation
and plasma concentrations of the chemokine RANTES. These
findings provide further support for the hypothesis that
clopidogrel has important anti-inflammatory actions that
may contribute to its clinical benefits.
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Figure 1 (A) Platelet–monocyte
aggregates, (B) platelet–neutrophil
aggregates, (C) monocyte surface
expression of CD40 and (D) monocyte
surface expression of CD11b before
and after four weeks’ treatment with
clopidogrel in patients with type 2
diabetes. MFI, mean fluorescence
intensity.
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Cardiac compression from a rheumatoid pericardial mass
A
75-year-old man presented with progressive dyspnoea.
There was a 24-year history of severe deforming
rheumatoid arthritis for which he had required a
number of disease modifying therapies. At the time of
admission his symptoms were controlled on non-steroidal
anti-inflammatory drugs (NSAIDs) and prednisolone. He had
no clinical signs of cardiac tamponade on presentation;
however, a chest radiograph showed an enlarged cardiac
silhouette and bilateral pleural effusions. A transthoracic
echocardiogram and computed tomographic (CT) scan of the
thorax (left panel) confirmed a large loculated pericardial
effusion with compression of the right ventricular cavity.
Aspiration of pleural fluid confirmed a transudate with a
normal glucose. Pericardiocentesis resulted in an improve-
ment in his symptoms. No malignant cells were seen and he
was discharged for outpatient follow up. His symptoms
recurred as did the pericardial effusion and he was
transferred to a cardiothoracic centre for surgery. At
operation a large and friable pericardial mass was debrided
and a pericardial window was performed. Histology revealed
fibrinous pericardium and chronic inflammatory infiltrates
(middle and right panels). There was a further recurrence at
four weeks and despite further drainage and aggressive
immunosuppression he did not recover and the postmortem
examination confirmed bilateral pulmonary emboli.
Pericardial compression in rheumatoid arthritis is rare.
Pericardiocentesis and the formation of a pericardial window
only provide temporary improvement and we suggest that the
definitive treatment should be a pericardectomy. To our
knowledge this is the only description of a histologically
proven rheumatoid inflammatory mass presenting as cardiac
compression.
P Bhat
B Chandrasekaran
E Barnes
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CT scan of the thorax showing a large
pericardial collection compressing the right
ventricle. There are also bilateral pleural
effusions.
Haematoxylin and eosin stain showing fibrous pericardium containing large numbers of
haemosiderin laden macrophages and a patchy chronic inflammatory infiltrate.
doi: 10.1136/hrt.2005.080952
Lipomatous metaplasia in myocardial infarction detected by cardiovascular magnetic resonance
A
64-year-old man with a prior history of anterior wall myocardial infarction treated with
thrombolysis in 1992, followed 10 years later by coronary artery bypass surgery,
underwent cardiovascular magnetic resonance examination (CMR) for quantification of
residual left ventricular function. Steady state free precession cine-CMR demonstrated thinned
myocardium with dyskinesis of the distal anteroseptal and apical left ventricular regions
consistent with an old myocardial infarction. Areas of unusual signal intensity compared to
that of the surrounding myocardium were noted on cine-CMR within the infarcted region.
These areas were confirmed to be composed of adipose tissue due to their characteristic high
signal intensity on T1-weighted turbo spin echo images and complete disappearance of signal
using fat suppression. The adipose tissue also had high signal intensity on two-dimensional
inversion recovery images obtained before administration of gadolinium-based contrast (see
panel) and was surrounded by areas of myocardial fibrosis demonstrated on late contrast-
enhanced (LCE) images. These findings are consistent with lipomatous metaplasia in the
region of an old myocardial infarction. This case demonstrates that a high signal intensity on
LCE images may not always represent fibrosis alone in regions of old myocardial infarction.
R Nijveldt
C B Marcu
A C van Rossum
R.Nijveldt@vumc.nl
Left ventricular outflow tract view; two-
dimensional inversion recovery image before
administration of contrast, arrows indicating
high signal intensity in infarcted area. Ao,
aorta; LA, left atrium; LV, left ventricle.
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